ArticleACS nanoscience Au2026
Hydrophobic Ion Pairing Improves Protein Thermal Stability and Lipid Nanocarrier Integration through Controlled Surface Modification.
Article in ACS nanoscience Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrating therapeutic proteins into lipid-based nanocarriers remains challenging due to fundamental incompatibilities between hydrophilic protein surfaces and lipophilic carrier matrices. Here, we demonstrate that controlled hydrophobic ion pairing (HIP) using lysozyme-sodium dodecyl sulfate (SDS) at stoichiometric ratios simultaneously improves thermal stability during pharmaceutical processing and lipid compatibility for nanocarrier integration. Building on our previous molecular characterization of lysozyme-SDS complexes, we investigated their application in nanostructured lipid carrier (NLC) formulations for oral protein delivery. SDS complexation preserved lysozyme enzymatic activity at processing-relevant temperatures and increased apparent lipid miscibility by 50% in both solid and liquid pharmaceutical lipid excipients. This enhanced compatibility translated directly into superior NLC performance, with complexed lysozyme achieving a 4-fold higher encapsulation efficiency (79.6 ± 1.8% vs 18.4 ± 4.3% for native protein) with improved batch-to-batch reproducibility. In simulated gastrointestinal conditions, lysozyme-SDS NLCs demonstrated sustained intestinal release (87.2 ± 16.5% over 6 h) with 67.5 ± 7.5% enzymatic activity retained compared to only 15.2 ± 3.0% activity for native lysozyme formulations. Mechanistic analysis from differential scanning calorimetry and crystallinity measurements showed that SDS complexation induces a molten globule-like protein state that reduces lipid packing (56.8% vs 68.6% crystallinity for native lysozyme), enabling superior matrix integration while maintaining biological function. These findings establish that controlled surface modification through HIP provides a systematic approach to overcome protein-lipid incompatibilities, offering a generalizable framework for developing lipid-based protein therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.